145 related articles for article (PubMed ID: 22484402)
1. Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer.
Sohn I; Jung WY; Sung CO
Gynecol Oncol; 2012 Jul; 126(1):103-8. PubMed ID: 22484402
[TBL] [Abstract][Full Text] [Related]
2. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
[TBL] [Abstract][Full Text] [Related]
4. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
5. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
6. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
[TBL] [Abstract][Full Text] [Related]
7. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
8. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
9. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
11. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
12. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
13. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma.
Barlin JN; Jelinic P; Olvera N; Bogomolniy F; Bisogna M; Dao F; Barakat RR; Chi DS; Levine DA
Gynecol Oncol; 2013 Mar; 128(3):512-7. PubMed ID: 23168173
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
[TBL] [Abstract][Full Text] [Related]
15. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
16. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
18. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
19. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
[TBL] [Abstract][Full Text] [Related]
20. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
